-
公开(公告)号：US20210024630A1
公开(公告)日：2021-01-28
申请号：US17040513
申请日：2019-03-26
发明人： Yi ZHU , Ole OLSEN , Dong XIA , David JELLYMAN , Katrina BYKOVA , Anne-Marie ROUSSEAU , Bill BRADY , Blair RENSHAW , Brian KOVACEVICH , Yu LIANG , Camilla WANG , Zeren GAO , Hui Huang
IPC分类号： C07K16/28 , A61P35/02 , C12N5/0783 , C12N5/09
摘要： The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).
-
公开(公告)号：US20220002417A1
公开(公告)日：2022-01-06
申请号：US16615112
申请日：2018-06-22
发明人： Brian KOVACEVICH , Dong XIA , Anne E. JENSEN , Jonathan K. FALLEN , Blair RENSHAW , Jeffrey B. Adamo , Phil TAN , Zeren GAO , Yi ZHU
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395 , A61P35/00
摘要： The application provides the anti-PD-L1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
-
公开(公告)号：US20210277109A1
公开(公告)日：2021-09-09
申请号：US16615116
申请日：2018-06-22
发明人： Ole OLSEN , Phil TAN , Dong XIA , David JELLYMAN , Brian KOVACEVICH , Bill BRADY , Blair RENSHAW , Zeren GAO , Yi ZHU
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
摘要： The application provides anti-ROR1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
-
公开(公告)号：US20210188989A1
公开(公告)日：2021-06-24
申请号：US16615119
申请日：2018-06-22
发明人： Ole OLSEN , Dong XIA , David JELLYMAN , Brian KOVACEVICH , Bill BRADY , Blair RENSHAW , Zeren GAO , Yi ZHU
摘要： The application provides anti-4-1BB monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
-
公开(公告)号：US20200347137A1
公开(公告)日：2020-11-05
申请号：US16760466
申请日：2018-11-02
发明人： Yi ZHU , Katrina BYKOVA , Bill BRADY , Blair RENSHAW , Dong XIA , Zeren GAO , Brian KOVACEVICH , Jonathan K. FALLON , Phil TAN
IPC分类号： C07K16/28
摘要： The disclosure provides bispecific antibodies having the binding specificity to at least two of human CTLA4, PD-1 or PD-L1. In one embodiment, the bispecific antibody comprises IgG domains having heavy chains and light chains, and two scFv components being connected to either C-terminal of the heavy chains or N-terminal of the light chains, wherein the IgG domains have the binding specificity to a first antigen, wherein the scFv components have the binding specificity to a second antigen, and wherein the first antigen and the second antigen are different and are independently selected from a-CTLA4, α-PD-1, and α-PD-L1.
-
公开(公告)号：US20200157217A1
公开(公告)日：2020-05-21
申请号：US16615109
申请日：2018-06-22
发明人： Ole OLSEN , Phil TAN , Dong XIA , David JELLYMAN , Brian KOVACEVICH , Bill BRADY , Blair RENSHAW , Zeren GAO , Yi ZHU
摘要： The applications provides the anti-CD3 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to active CD3+ T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
-
公开(公告)号：US20240067741A1
公开(公告)日：2024-02-29
申请号：US18358834
申请日：2023-07-25
发明人： Ole OLSEN , Dong XIA , David JELLYMAN , Brian KOVACEVICH , Bill BRADY , Blair RENSHAW , Zeren GAO , Yi ZHU
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , C07K16/2803 , A61K2039/505
摘要： The application provides anti-4-1BB monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
-
公开(公告)号：US20230322920A1
公开(公告)日：2023-10-12
申请号：US18296871
申请日：2023-04-06
发明人： Yi ZHU , Ole OLSEN , Dong XIA , David JELLYMAN , Katrina BYKOVA , Anne-Marie K. ROUSSEAU , Bill BRADY , Blair RENSHAW , Brian KOVACEVICH , Yu LIANG , Zeren GAO
IPC分类号： C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06
CPC分类号： C07K16/2803 , A61K47/6803 , A61K39/3955 , A61K45/06 , C07K16/2809 , C07K16/2827 , C07K16/2863 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73
摘要： The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.
-
公开(公告)号：US20210008113A1
公开(公告)日：2021-01-14
申请号：US17040519
申请日：2019-03-26
发明人： Yi ZHU , Ole OLSEN , Jahan KHALILI , Dong XIA , David JELLYMAN , Katrina BYKOVA , Anne-Marie ROUSSEAU , Camilla WANG , Zeren GAO , Hui HUANG , Steven K. LUNDY
IPC分类号： A61K35/17 , C12N5/0783 , G01N33/574 , C07K14/725 , C07K14/705 , C07K16/28 , A61P35/00
摘要： The application provides methods for generating a therapeutic composition. The method includes the steps of providing a cell material comprising a cytotoxic cell, incubating the cell material with a first GNC protein to provide an activated cell composition, wherein the activated cell composition comprises a first therapeutic cell, and formulating the activated cell composition to provide a therapeutic composition, wherein the therapeutic composition is substantially free of exogenous viral and non-viral DNA or RNA. The first GNC protein comprises a first cytotoxic binding moiety and a first cancer targeting moiety, wherein the first cytotoxic binding moiety has a specificity to a first cytotoxic cell receptor and is configured to activate the first cytotoxic cell, and wherein the first cancer targeting moiety has a specificity to a first cancer cell receptor. The first therapeutic cell comprises the first GNC protein bound to the cytotoxic cell through the first cytotoxic cell receptor.
-
公开(公告)号：US20200157224A1
公开(公告)日：2020-05-21
申请号：US16615123
申请日：2018-06-22
发明人： Yi ZHU , Ole OLSEN , Dong XIA , David JELLYMAN , Katrina BYKOVA , Anne-Marie K. ROUSSEAU , Bill BRADY , Blair RENSHAW , Brian KOVACEVICH , Yu LIANG , Zeren GAO
摘要： The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a second scFv domain, a Fab domain, a Fc domain, and a third scFv at the C-terminal, wherein the first scFv domain, the second scFv domain, the Fab domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. In one embodiment, the antigen includes CD19, CD3, CD137, 4-1BB, and PD-L1. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.017 秒)
